Literature DB >> 11157640

Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range.

J Hirsh1, J Dalen, D R Anderson, L Poller, H Bussey, J Ansell, D Deykin.   

Abstract

Mesh：

Substances：

Year:  2001        PMID： 11157640     DOI： 10.1378/chest.119.1_suppl.8s

Source DB:  PubMed          Journal:  Chest        ISSN： 0012-3692            Impact factor:   9.410


× No keyword cloud information.
  203 in total

1.  Short report: managing anticoagulation. Comparison of results at three primary care centres.

Authors:  Ross E G Upshur; Christine Papoushek; Denis Macdonald; Guilherme Dantas
Journal:  Can Fam Physician       Date:  2003-02       Impact factor: 3.275

2.  High-risk antimicrobial prescriptions among ambulatory patients on warfarin.

Authors:  M A Lane; S T Devine; J R McDonald
Journal:  J Clin Pharm Ther       Date:  2011-04-24       Impact factor: 2.512

Review 3.  Implication from randomized trials of rate and rhythm controls on management of patients with persistent atrial fibrillation.

Authors:  Vincent E Hagens; Dirk J Van Veldhuisen; Harry J G M Crijns; Isabelle C van Gelder
Journal:  Ann Noninvasive Electrocardiol       Date:  2006-04       Impact factor: 1.468

4.  British Thoracic Society guidelines for the management of suspected acute pulmonary embolism.

Authors: 
Journal:  Thorax       Date:  2003-06       Impact factor: 9.139

5.  Age and first INR after initiation of oral anticoagulant therapy with acenocoumarol predict the maintenance dosage.

Authors:  Johanna H H van Geest-Daalderop; Barbara A Hutten; Augueste Sturk; Marcel M Levi
Journal:  J Thromb Thrombolysis       Date:  2003-06       Impact factor: 2.300

Review 6.  [Current controversies in the diagnosis and management of cerebral venous and dural sinus thrombosis].

Authors:  S Schwarz; M Daffertshofer; T Schwarz; D Georgiadis; R W Baumgartner; M Hennerici; C Groden
Journal:  Nervenarzt       Date:  2003-08       Impact factor: 1.214

7.  Hydroxywarfarin metabolites potently inhibit CYP2C9 metabolism of S-warfarin.

Authors:  Drew R Jones; So-Young Kim; Michael Guderyon; Chul-Ho Yun; Jeffery H Moran; Grover P Miller
Journal:  Chem Res Toxicol       Date:  2010-05-17       Impact factor: 3.739

8.  Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups.

Authors:  Stuart A Scott; Rame Khasawneh; Inga Peter; Ruth Kornreich; Robert J Desnick
Journal:  Pharmacogenomics       Date:  2010-06       Impact factor: 2.533

9.  VKORC1-1639A allele influences warfarin maintenance dosage among Blacks receiving warfarin anticoagulation: a retrospective cohort study.

Authors:  Fatima Donia Mili; Tenecia Allen; Paula Weinstein Wadell; W Craig Hooper; Christine De Staercke; Christopher J Bean; Cathy Lally; Harland Austin; Nanette K Wenger
Journal:  Future Cardiol       Date:  2017-12-08

10.  Characterization of inhibition kinetics of (S)-warfarin hydroxylation by noscapine: implications in warfarin therapy.

Authors:  Nan Zhang; Ryan P Seguin; Kent L Kunze; Yan-Yan Zhang; Hyunyoung Jeong
Journal:  Drug Metab Dispos       Date:  2013-09-17       Impact factor: 3.922
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.